Cullinan Therapeutics, Inc. (CGEM) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Cullinan Therapeutics reported revenue of $0. Net income was -$219.9M. Operating activities generated -$175.8M of cash, leaving -$175.8M of free cash flow. At fiscal year end, Cullinan Therapeutics held $448.4M in total assets against $39.6M in total liabilities, including $88.3M of cash and equivalents.
Open the full interactive Cullinan Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Cullinan Therapeutics Key Stats
| Share Price | $14.10 |
|---|---|
| 52-Week Range | $7.19 – $22.95 |
| Shares Outstanding | 58.3 million (basic, 2024 Q3) |
Cullinan Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $18.9M | $0 | $0 | $0 | $0 |
| Operating Income | -$68.0M | $144.6M | -$191.1M | -$196.9M | -$241.6M |
| Pre-Tax Income | -$65.6M | $151.3M | -$169.2M | -$167.5M | -$219.9M |
| Income Tax | — | $42.1M | -$14.1M | $117,000 | $0 |
| Net Income | -$65.6M | $111.2M | -$153.2M | -$167.4M | -$219.9M |
| Diluted EPS | -$1.52 | $2.38 | -$3.69 | — | — |
Cullinan Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$50.6M | -$50.7M | -$49.7M | -$53.7M |
Cullinan Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $59.8M | $156.2M | $98.4M | $83.0M | $88.3M |
| Current Assets | $296.6M | $474.5M | $480.2M | $414.7M | $386.8M |
| Total Assets | $437.2M | $561.1M | $484.2M | $621.8M | $448.4M |
| Current Liabilities | $11.7M | $22.5M | $28.1M | $30.6M | $37.7M |
| Total Long-Term Debt | — | — | $2.0M | — | — |
| Total Liabilities | $11.8M | $26.1M | $30.3M | $31.5M | $39.6M |
| Shareholders' Equity | $425.0M | $535.0M | $453.7M | $590.3M | $408.7M |
Cullinan Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$43.4M | -$126.7M | -$134.3M | -$145.3M | -$175.8M |
| Cash From Investing | -$333.8M | $249.0M | $35.8M | -$136.3M | $180.0M |
| Cash From Financing | $268.8M | -$25.9M | $40.8M | $266.2M | $1.1M |
| Free Cash Flow | -$43.4M | -$127.8M | -$134.5M | -$145.3M | -$175.8M |
Figures from Cullinan Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cullinan Therapeutics financials page for every line item.
Cullinan Therapeutics Company Profile
| Ticker | CGEM |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001789972 |
Frequently Asked Questions
What was Cullinan Therapeutics' revenue in fiscal 2025?
Cullinan Therapeutics (CGEM) reported revenue of $0 for fiscal 2025.
What is Cullinan Therapeutics' annual revenue history?
Cullinan Therapeutics' annual revenue by fiscal year: 2021: $18.9M; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cullinan Therapeutics' net income in fiscal 2025?
Cullinan Therapeutics reported net income of -$219.9M for fiscal 2025.
How much free cash flow did Cullinan Therapeutics generate in fiscal 2025?
Cullinan Therapeutics generated -$175.8M of free cash flow in fiscal 2025.
What was Cullinan Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cullinan Therapeutics reported revenue of $0.
How many shares of Cullinan Therapeutics are outstanding?
Cullinan Therapeutics reported a weighted average of 58.3 million basic shares outstanding in 2024 Q3.
When does Cullinan Therapeutics' fiscal year end?
Cullinan Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Cullinan Therapeutics headquartered?
Cullinan Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.
Cullinan Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →